Document is current

Article History

Accepted: 31 January 2023

First Online: 3 March 2023

Declarations

:

: S.K. reports, outside the submitted work, nonfinancial support from Lilly France, Novo Nordisk, Novartis Pharma, Roche diabetes care, Lifescan, Abbott France, Sanofi, ViiV Healthcare, Servier, Becton Dickinson, and personal fees from Icomed, Pascaleo, BT3SI, M3global research. J.B. reports, outside the submitted work, personal fees from Abbott, Bayer, Bottu, Ferring, Steripharma, Kantar, Teriak, personal fees and non-financial support from Pfizer, Quantum Genomics, personal fees from Sanofi and Servier. All other authors (GL, CG, AG, NR, CDT, VT, GPB, JB, and VO) declare no conflict of interest that might be relevant to this work.

: This work was supported by the French Cardiology Federation (Thematic grant 2019: cardiovascular diseases in women), the French Hypertension Society (SFHTA) and the French Hypertension Research Foundation (FRHTA). The funders had no role in the study design, data collection, data analysis, decision to publish, or drafting of the manuscript.

: VO, JB, CDT, SK, VT, NR and GPB conceived and designed the analysis. GL, AG and CG collected the data and performed the analysis. GL wrote the paper under the supervision of VO and JB.

: In line with French national regulations and ethics committee, Institutional Review Board (IRB) approval was not required for this study.

: Santé Publique France—the French public health agency—has full and chronic access to the SNDS (governmental deliberation no. 2016–316, 13 October 2016). We cannot share National Health Data System data as they are only available on a secure portal. Authorization to access this portal needs registration and clearance.

: Not applicable.

: Not applicable.

: Not applicable.